Dihydropyrimidine Dehydrogenase Testing for Cancer Treatment

Rationale for DPD Testing

The European Society for Medical Oncology (ESMO) guidelines recommend testing for DPD deficiency before initiating 5-FU-based chemotherapy 1

The European Society for Medical Oncology (ESMO) guidelines explicitly recommend testing for DPD deficiency before starting treatment with topical fluorouracil 1
For patients with partial DPD deficiency, consider alternative treatments for actinic keratosis such as cryotherapy, imiquimod, or photodynamic therapy, as recommended by the American Academy of Dermatology 2
If topical 5-FU must be used in patients with partial DPD deficiency, consider treating smaller areas and monitor closely for signs of systemic toxicity, according to the British Association of Dermatologists 3
For patients with partial DPD deficiency, consider treating smaller areas and monitor closely for signs of systemic toxicity, as suggested by the British Association of Dermatologists 4